Image: Guerbet celebrates its 90th year in 2016 (Photo courtesy of iStock).
Guerbet (Paris, France), a specialist in contrast agents and solutions for medical imaging, will be celebrating its 90th year on November 15, 2016. The Group is one of the leading players in medical imaging worldwide and offers a full range of medical solutions and services.
The company is named after the French chemist Marcel Guerbet who discovered the world’s first iodinated contrast agent Lipidol, in 1901. His son André Guerbert, founded the company on November 15, 1926. Following the acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business, finalized a year ago, Guerbet has grown from being an essentially France-focused company to an international group. Today, 83% of Guerbet’s sales are generated outside France, driven by its four growth engines: contrast agents for MRI, contrast agents for X-ray imaging, Interventional Radiology and Theranostics and Imaging Solutions and Services, including medical devices such as injectors.
Guerbet announced the celebration of its 90th anniversary at the French Radiology Congress, which was held in Paris from October 14 to 17, where a fresco featuring the outstanding dates in the company’s history was unveiled in the presence of the President of the French Radiology Society. Over the coming months, Guerbet’s sites worldwide will be organizing events associating their employees and their external audiences in line with its celebration of “90 years of passion.” Guerbet’s website also features a video illustrating 90 years of the company’s history.
Yves L’Epine, Guerbet CEO, said, “Guerbet, which has already been through many turning points, is currently experiencing a key period in its history. It is both particularly exciting and demanding time for our teams. We are in the process of successfully integrating our major acquisition to build a new global leader in medical imaging which is innovative and respectful of all its partners.” He added, “More than ever, we are driven to offer indispensable solutions for diagnostic and interventional imaging all over the world. Faced with the challenges of aging, the development of chronic diseases and certain cancers that remain difficult to treat, medical imaging opens up an exceptional range of responses which augur well for great progress for patients.”